HKD 0.62
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 471.2 Million CNY | 9.88% |
2022 | 428.83 Million CNY | 162.62% |
2021 | 163.29 Million CNY | 4.28% |
2020 | 156.59 Million CNY | -88.11% |
2019 | 1.31 Billion CNY | 451.17% |
2018 | 239.01 Million CNY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 467.75 Million CNY | 0.0% |
2023 Q4 | 471.2 Million CNY | 0.0% |
2023 FY | 471.2 Million CNY | 9.88% |
2023 Q2 | 297.06 Million CNY | 0.0% |
2022 FY | 428.83 Million CNY | 162.62% |
2022 Q4 | 481.47 Million CNY | 0.0% |
2022 Q2 | 259.62 Million CNY | 0.0% |
2021 Q2 | 156.33 Million CNY | 0.0% |
2021 FY | 163.29 Million CNY | 4.28% |
2021 Q4 | 199.75 Million CNY | 0.0% |
2020 Q2 | 1.81 Billion CNY | 0.0% |
2020 FY | 156.59 Million CNY | -88.11% |
2020 Q4 | 185.66 Million CNY | 0.0% |
2019 Q2 | - HKD | 0.0% |
2019 Q4 | 1.47 Billion CNY | 0.0% |
2019 FY | 1.31 Billion CNY | 451.17% |
2018 FY | 239.01 Million CNY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Uni-Bio Science Group Limited | 152.81 Million HKD | -208.343% |
CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 93.324% |